Aigen Investment Management LP Purchases Shares of 7,161 Novo Nordisk A/S (NYSE:NVO)

Aigen Investment Management LP acquired a new position in Novo Nordisk A/S (NYSE:NVO - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 7,161 shares of the company's stock, valued at approximately $741,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NVO. Pacific Center for Financial Services lifted its holdings in Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company's stock worth $25,000 after purchasing an additional 135 shares during the last quarter. Bell Investment Advisors Inc boosted its stake in shares of Novo Nordisk A/S by 79.9% in the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company's stock valued at $26,000 after purchasing an additional 127 shares in the last quarter. CNB Bank acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at $26,000. Tyler Stone Wealth Management increased its holdings in shares of Novo Nordisk A/S by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company's stock worth $27,000 after buying an additional 146 shares in the last quarter. Finally, West Paces Advisors Inc. increased its holdings in shares of Novo Nordisk A/S by 100.0% during the third quarter. West Paces Advisors Inc. now owns 300 shares of the company's stock worth $27,000 after buying an additional 150 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Down 0.8 %

NVO stock traded down $1.07 during midday trading on Wednesday, reaching $134.09. The stock had a trading volume of 2,682,085 shares, compared to its average volume of 4,671,824. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. Novo Nordisk A/S has a twelve month low of $75.56 and a twelve month high of $138.28. The firm has a market cap of $601.73 billion, a price-to-earnings ratio of 46.24, a PEG ratio of 1.86 and a beta of 0.43. The business has a fifty day simple moving average of $128.11 and a two-hundred day simple moving average of $116.07.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. BMO Capital Markets initiated coverage on Novo Nordisk A/S in a report on Friday, April 12th. They set an "outperform" rating and a $163.00 price target for the company. Morgan Stanley began coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They issued an "overweight" rating and a $120.00 target price for the company. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.